Georgetown University and The Michael J. Fox Foundation for Parkinson’s Research Offer Fellowship in Regulatory Science
Posted in News Release | Tagged aging, brain, Parkinson's disease
WASHINGTON and NEW YORK (June 1, 2016) — Georgetown University Medical Center and The Michael J. Fox Foundation for Parkinson’s Research announce a fellowship in regulatory science that will promote postgraduate training in the Parkinson’s research field to optimize clinical trial design and support approval of novel therapies.
The Michael J. Fox Foundation (MJFF) will fund a fellowship through Georgetown’s Program for Regulatory Science & Medicine for one postgraduate researcher who will work with mentors from academia, industry and the U.S. Food and Drug Administration (FDA) to investigate an aspect of Parkinson’s research design.
“While momentum grows in improved understanding of Parkinson’s dysfunction and in drug development, it is important to keep pace in regulatory science,” said MJFF CEO Todd Sherer, PhD. “New treatments addressing unmet symptoms and integration of technology in clinical trials present opportunity for coordination with regulators to advance these programs.”
Regulatory science generates and makes use of evidence-based knowledge to inform decision-making about the safety and benefits of medical products and comprises an emerging, specialized and interdisciplinary field of biomedical research and education.
“This is an important, burgeoning field that advances science and medicine, a reflection of the continuum upon which scientific discovery is made and translated,” said Erin Wilhelm, MPH, executive director of the Program for Regulatory Science & Medicine. “Support from organizations such as The Michael J. Fox Foundation for mentored training opportunities is critical to prepare tomorrow’s disease specialists.”
Ira Shoulson, MD, professor of neurology, pharmacology and human science and director of the Program for Regulatory Science and Medicine at Georgetown University, and member of the MJFF Executive Scientific Advisory Board, will serve as academic mentor for this fellow.
“The pace of Parkinson’s innovation is invigorating, but we need to tailor our studies for optimal proof of concept and efficacy testing. Guidance from across academia, industry and the FDA will build a platform for this fellow to shape the direction of research,” said Shoulson.
Applications for the regulatory science fellowship are due Friday, July 29, 2016, and the fellowship Leadership and Advisory Committee composed of representatives from Georgetown, MJFF and FDA will choose a fellow by Friday, September 2, 2016. The first term will begin in October 2016 with a one-year term, with possibility for renewal. The fellow will receive up to two years of salary support and research stipends.
To learn more about the program or to apply, visit
http://regulatoryscience.georgetown.edu/RS-fellowship or email questions to email@example.com.
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.
About the Michael J. Fox Foundation
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $600 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us on the Web (new window), Facebook (new window), Twitter (new window), and LinkedIn (new window).